Quantcast

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Research paper by Dana R. Leach, Matthew F. Krummel, James P. Allison

Indexed on: 03 Oct '18Published on: 22 Mar '96Published in: Science



Abstract

One reason for the poor immunogenicity of many tumors may be that they cannot provide signals for CD28-mediated costimulation necessary to fully activate T cells. It has recently become apparent that CTLA-4, a second counterreceptor for the B7 family of costimulatory molecules, is a negative regulator of T cell activation. Here, in vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors. Furthermore, this rejection resulted in immunity to a secondary exposure to tumor cells. These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells.